Content Rheum
Interleukin-23 Inhibition
FAQs
Click a title to watch the FAQ
​
Define, compare, and contrast humoral and cell-mediated immunity.
​
​
What is the role of the IL23/IL17 axis in rheumatic disease?
​
Provide immunologic rationale For IL23 directed therapy in PsA, PsO, and IBD.
​
Why is binding CD64+ important when discussing IL23 directed therapy?
​
How does axial PsA differ from AS clinically, genetically, and radiographically?
​
How do you interpret radiographic progression using modified-vdHS or mTSS?
​
How does real-world evidence differ from randomized controlled trials?
​
How do you interpret cDAPSA/DAPSA and MDA?
​
How do IL-23 and IL-17 inhibitors differ in clinical efficacy?
MEDICATION REVIEWS
Click a title to watch the review
​
Describe the mechanism of action of guselkumab.
​​​
What is non-responder imputation and how is it utilized in clinical trials?
​
How is guselkumab dosed in PsO, PsA, and IBD?
​
What is the safety profile of guselkumab in PsO and PsA?
​
What is the efficacy of guselkumab across the GRAPPA domains?
​
JOURNAL CLUBS
Click a title to read the journal
Differentiation of therapeutic antibodies targeting Interleukin (IL)-23.
​
​
​
Long-term guselkumab safety in Psoriasis & PsA (Phase II/III Analysis).
PODCASTS
Click a title to play the podcast
The IL23/IL17 cascade and implications in the pathogenesis of PsA, PsO, and IBD.
​
CD64+ binding: description, relevance, and potential clinical implications.
​
The clinical utility of guselkumab in axial PsA.
​
The relative persistency and effectiveness of guselkumab in the real-world.
